Recent News

• 04.24.2025 - Health Answers by Pfizer Wins Webby’s People’s Voice Award
• 04.04.2025 - A Phase 2 Open-Label, Single Arm Study of Tucatinib in Combination with Trastuzumab and Capecitabine in Participants with Previously Treated Locally Advanced Unresectable or Metastatic HER2+ Breast Carcinoma
• 04.01.2025 - March Social Media Round-Up—Annual Review, Fast Company, and More

Recent Filings

• 04.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.11.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.10.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.10.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.10.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.07.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities